Shoulder Innovations Q1 revenue up 65% to $16.7M, raises FY2026 guidance to $65-68M

SHOULDER INNOVATIONS, INC.

Net revenue $16.7M (+65% YoY); implant systems sold 2,184 (+51%); gross margin 77.7%.
Raised FY2026 net revenue guidance to $65-68M from $62-65M, representing 37-44% YoY growth.
Operating loss $9.0M, net loss $8.4M; adjusted EBITDA loss $7.0M; cash and marketable securities $108.5M.
Full commercial launch of InSet I-135RFX Humeral Stem after FDA clearance for additional fracture indications.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

SHOULDER INNOVATIONS, INC. reported the first quarter ended March 31, 2026 results: revenue $16.7 million, net income $8.4 million. Guidance raised.

Period: the first quarter ended March 31, 2026
Revenue: $16.7 million
Net income: $8.4 million
Guidance: raised
Result: reported results

Exact text from the filing

the shoulder surgical care market, today reported financial results for the first quarter ended March 31, 2026. First Quarter Financial Highlights • Generated net revenue of $16.7 million in the first quarter, a 65% increase over the first quarter of 2025 • Achieved gross margin of 77.7% for the first quarter compared to 76.9% for the first quarter of 2025 •

View on SEC.gov

171 earnings releases filed in the last 30 days. Browse all earnings releases →

SHOULDER INNOVATIONS, INC. filing history →

Source: SEC EDGAR

accession 0001699350-26-000033

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.